Releases
PLXP
--
0.00%
--
  • All
  • Financials
  • Insiders
More
Webull provides the latest PLx Pharma (PLXP) stock and general news. This information may help you make smarter investment decisions.
About PLXP
PLx Pharma Inc. is a late-stage specialty pharmaceutical company. It is focusing on developing clinically-validated and patent-protected PLxGuard delivery system. Its lead product, Vazalore 325 mg, which is a formulation of aspirin using the PLxGuard delivery system intended to provide antiplatelet for cardiovascular disease prevention as compared to the current standard of care, enteric-coated aspirin, and significantly reduce gastric side effects. The Company has also developed Vazalore 81 mg, a lower-dose companion product for Vazalore 325 mg. The PLxGuard delivery system uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs to selectively release these drugs to targeted portions of the GI tract. Its product pipeline also includes other oral NSAIDs using the PLxGuard delivery system that may be developed, including a clinical-stage, GI-safer ibuprofen, PL1200 Ibuprofen 200 mg, for pain and inflammation.